[12] Patent
[11] Patent No.:GC0007586  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126037
Date of the Decision to Grant the Patent:15/Apr/2018

[21] Application No.:GCC/P/2006/6382

[22] Filing Date:7/6/2006

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
US
8/6/2005
8/12/2005
05105023.5
11/296,918

[72] Inventors:1- Lancois, David Francis Alain،2- Andries, Koenraad Jozef Lodewijk Marcel،3- Koul, Anil،4- Pasquier, Elisabeth Therese Jeanne،5- Guillemount, Jerome Emile Georges

[73] Owner: JANSSEN PHARMACEUTICA N. V., Turnhoutseweg 30, Beerse, B-2340, Belgium

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K ; A61P ; C07D (2006.01)

[56] Cited Documents:

-WO 2004011436 A (JANSSEN PHARMACEUTICA N.V; VAN GESTEL, JOZEF, FRANS, ELISABETHA; GUILL) 5 February 2004
-ANDRIES K ET AL: “A DIARYLQUINOLINE DRUG ACTIVE ON THE ATP SYNTHASE OF MYCOBACTERIUM TUBERCULOSIS“
SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 307, 14 January 2005
-WO 9506047 A (FUJISAWA PHARMACEUTICAL CO., LTD; NAKAMURA, HIDEKO; OHKI, HIDENORI; YA) 2 March 1995
-WO 2005117875 A (JANSSEN PHARMACEUTICA N.V; ANDRIES, KOENRAAD, JOZEF, LODEWIJK, MARCEL;) 15 December 2005
-WO 2005070924 A (JANSSEN PHARMACEUTICA N.V; GUILLEMONT, JEROME, EMILE, GEORGES; PASQUIE) 4 August 2005
 
Examiner: Hanien H Al Ghannami

[54] QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
[57] Abstract: The present invention relates to the use of a compound for the manufacture of a medicament for the treatment of a bacterial infection, said compound being a compound of formula: a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, polyhaloC1-6alkyl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxy, Ar or Het; p is an integer equal to 1 or 2; R2 is C1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy or C1-6alkylthio; R3 is C1-6alkyl, Ar, Het or Het1; R4 and R5 each independently are hydrogen, C1-6alkyl or benzyl; or R4 and R5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, each of said rings may optionally be substituted with C1-6alkyl, halo, polyhaloC1-6alkyl, hydroxy, hydroxyC1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino, C1-6alkylthio, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl or pyrimidinyl; R6 is hydrogen, halo, polyhaloC1-6alkyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio; or two vicinal R6 radicals may be taken together to form a bivalent radical of formula -CH=CH-CH=CH- ; r is an integer equal to 1 or 2; R7 is hydrogen, C1-6alkyl, Ar, Het or Het1; provided that the bacterial infection than a Mycobacterial infection.
No. of claims: 37


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.